Curated dataset · n=61 verified deals · Not live market data · Scores are descriptive, not forecasts.
You are here

Deals — Network graph, deal flow, valuation matrix, and acquirer landscape.

Cogentix Medical
→
Laborie Medical Technologies

Acquisition · Cash · announced Mar 12, 2018

View in network
  1. Announced

    Mar 12, 2018

  2. Closed

    Apr 23, 2018

Economics

Cash()

Pre-deal · pre-deal mark: 2018, year precision · Laborie Medical Technologies press release — Cogentix acquisition, 2019

$3.85/share, ~$214M enterprise value

Target

Cogentix Medical

Pelvic Health · Clinical / therapeutic

HQ Minnetonka, MN · Founded 1997

Urogynecology devices — Urgent PC neuromodulation (percutaneous tibial nerve stimulation for overactive bladder) and PrimeSight cystoscopy with EndoSheath protective barrier

  • SEC EDGAR — Cogentix Medical merger filing (Mar 12, 2018)
  • Laborie Medical press release (Apr 23, 2019 — completion)

Acquirer

Laborie Medical Technologies

Pelvic Health

HQ Mississauga, Canada

Why this buyer

Curated copy from the verified dataset — not an 8-K LLM summary

Urgent PC neuromodulation and PrimeSight cystoscopy expand Laborie's urology/urogynecology portfolio — addresses overactive bladder and stress urinary incontinence

Evidence ladder

Dual-source corroborationValue disclosed
  1. Primary (regulatory / filing)

    SEC EDGAR — Cogentix Medical merger filing (Mar 12, 2018)

  2. Tertiary (trade / analyst)

    Laborie completion (Apr 23, 2018)

  3. Primary (regulatory / filing)

    SEC EDGAR 8-K (Cogentix, Mar 12, 2018 — merger agreement) https://www.sec.gov/Archives/edgar/data/894237/000114036118013088/form8k.htm

    Open source
  4. Primary (regulatory / filing)

    SEC EDGAR 8-K (Cogentix, Apr 24, 2018 — merger consummated Apr 23, 2018) https://www.sec.gov/Archives/edgar/data/894237/000119312518127561/d569300d8k.htm

    Open source

Limitations

  • $3.85/share, ~$214M enterprise value
  • Pre-deal valuation sourced from: Laborie Medical Technologies press release — Cogentix acquisition, 2019. Pre-deal market-cap and funding citations do not corroborate the acquisition.

Valuation peers · Pelvic Health

Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.

Why included
Nine Continents MedicalColoplastNov 3, 2020same evidence class

Other verified deals by Laborie Medical Technologies

Acquirer program history not already listed as a valuation peer or adjacency row.

No further verified deals

Other verified transactions by Laborie Medical Technologies are already listed above, or none are in the dataset.

Patient empowerment context

Patient empowerment baseline (HLTH 2022)

No curated mapping — Cogentix Medical (Pelvic Health). HLTH/Outcomes4Me 2022 baseline is Breast cancer care continuum (HLTH 2022). No curated mapping for this target in the verified crosswalk.

Research workspace (includes heuristic crosswalk) →

Related verified workspaces

Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.

Curated verified dataset v11 · updated 2026-10-19 · 4 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.